Table 2. Univariate and multivariate analyses of factors associated with PFS of lung cancer patients treated with immunotherapy.

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (years)		0.005		0.048
<51	1.94 [1.22–.09]		1.95 [1.01–3.78]
≥51	Ref		Ref
Gender		0.793
Female	1.07 [0.67–1.70]
Male	Ref
Pathology		0.938
Adenocarcinoma	1.08 [0.63–1.85]
SCC	1.11 [0.64–1.94]
Others	Ref
Smoking		0.435
Yes	0.84 [0.54–1.31]
No	Ref
BSA		0.063
<1.94	1.96 [0.96–4.00]
≥1.94	Ref
BMI		0.118
<28.1	0.50 [0.21–1.19]
≥28.1	Ref
Clinical stage		0.049
III	0.58 [0.34–0.99]
IV	Ref
WBC		0.021
<6.59	1.58 [1.07–2.32]
≥6.59	Ref
NEU		0.149
<4.80	1.35 [0.90–2.04]
≥4.80	Ref
LYM		0.014
<0.86	1.79 [1.12–2.86]
≥0.86	Ref
PLT		0.067
<323	1.90 [0.96–3.76]
≥323	Ref
MON		0.020		0.025
<0.50	1.58 [1.08–2.33]		1.74 [1.07–2.81]
≥0.50	Ref		Ref
AEC		0.005
<0.24	2.17 [1.26–3.76]
≥0.24	Ref
HB		0.006
<130	1.71 [1.16–2.52]
≥130	Ref
CRP		0.074
<32.09	0.46 [0.20–1.08]
≥32.09	Ref
LDH		0.043		0.030
<241	0.63 [0.40–0.98]		0.59 [0.36–0.95]
≥241	Ref		Ref
ALP		0.055
<109	1.54 [0.99–2.39]
≥109	Ref
ALB		0.005		0.084
<37.8	1.79 [1.19–2.69]		1.58 (0.94-2.66)
≥37.8	Ref		Ref
PLR		0.074
<231.8	0.70 [0.47–1.04]
≥231.8	Ref
NLR		0.204
<3.67	0.78 [0.53–1.15]
≥3.67	Ref
LMR		0.138
<4.29	0.68 [0.41–1.13]
≥4.29	Ref
Line		0.029		0.026
First line	0.63 [0.42–0.95]		0.57 [0.35–0.94]
After first line	Ref		Ref
Chest radiotherapy		0.555
Yes	1.14 [0.75–1.73]
No	Ref
Radical surgery		0.479
Yes	0.86 [0.55–1.32]
No	Ref
PD-L1		0.503
<50%	1.35 [0.56–3.22]
≥50%	Ref
Drug use		0.859
ICI alone	1.04 [0.70–1.53]
ICI combination	Ref
Types of ICIs		0.643
Pembrolizumab	0.83 [0.49–1.42]
Tislelizumab Others	0.74 [0.39–1.39] Ref